U.S. Packaging Stock News

NasdaqGS:HURN
NasdaqGS:HURNProfessional Services

Huron Consulting Group (HURN) Margin Compression Challenges Bullish Earnings Growth Narratives

Huron Consulting Group (HURN) closed out FY 2025 with fourth quarter revenue of US$468.6 million and basic EPS of US$1.77, against a backdrop of trailing twelve month revenue of about US$1.7 billion and EPS of US$6.02 and a reported earnings decline over the most recent year. The company has seen quarterly revenue move from US$388.4 million in Q4 2024 to US$468.6 million in Q4 2025, while basic EPS shifted from US$1.92 to US$1.77 as trailing net profit margins moved from 7.8% to 6.2%, setting...
NasdaqGS:FLYW
NasdaqGS:FLYWDiversified Financial

Flywire (FLYW) Thin Margins And 113x P/E Test Bullish Profitability Narrative

Flywire (FLYW) just wrapped up FY 2025 with Q4 revenue of US$157.5 million and basic EPS of roughly US$0.00, capping a trailing 12 month stretch where revenue reached US$623.0 million and EPS came in at US$0.11. Over recent periods, the company has seen quarterly revenue move from US$117.6 million in Q4 2024 to US$157.5 million in Q4 2025, while basic EPS shifted from a loss of US$0.13 to near break even. This sets the stage for investors to focus closely on how margins are being managed from...
NasdaqGS:EXLS
NasdaqGS:EXLSProfessional Services

ExlService Holdings (EXLS) Margin Improvement Supports Bullish Narratives In FY 2025 Earnings

ExlService Holdings (EXLS) has wrapped up FY 2025 with fourth quarter revenue of US$542.6 million and basic EPS of US$0.38, while trailing twelve month figures show revenue at about US$2.1 billion and EPS at US$1.56, alongside 26.6% earnings growth over the past year. The company has seen quarterly revenue move from US$481.4 million in Q4 2024 to US$542.6 million in Q4 2025, with basic EPS shifting from US$0.31 to US$0.38 over the same period. This sets up a story in which improving net...
NasdaqCM:IGIC
NasdaqCM:IGICInsurance

International General Insurance (IGIC) Margin Dip Tests Narrative Of Earnings Stability

International General Insurance Holdings (NasdaqCM:IGIC) has wrapped up FY 2025 with fourth quarter total revenue of US$126.4 million and basic EPS of US$0.76, alongside trailing twelve month revenue of US$516.9 million and EPS of US$2.89. Over the past few quarters, revenue has moved from US$129 million and EPS of US$0.59 in Q1 2025 to US$132.9 million with EPS of US$0.77 in Q2, then US$128.6 million and EPS of US$0.75 in Q3, before landing at the latest Q4 figures. This gives investors a...
NasdaqGS:FWRD
NasdaqGS:FWRDLogistics

Forward Air (FWRD) Quarterly Losses Challenge Margin Recovery Narratives Despite Stable Revenue

Forward Air (FWRD) has wrapped up FY 2025 with Q4 revenue of US$631.2 million and a basic EPS loss of US$0.91, while trailing twelve month EPS sits at a loss of US$3.51 on revenue of about US$2.5 billion. Over recent quarters the company has seen revenue move in a tight band between US$613.3 million and US$655.9 million, while basic EPS has remained in loss territory, ranging from a loss of US$0.41 to US$2.59 per quarter. For investors, this latest set of numbers keeps the spotlight firmly on...
NasdaqGS:MDLN
NasdaqGS:MDLNMedical Equipment

Medline (MDLN) Margin Improvement To 4.6% Tests Bullish Earnings Growth Narratives

Medline (MDLN) just posted its FY 2025 third quarter scorecard with revenue of US$7.1b, basic EPS of US$0.018, and trailing 12 month earnings growth of 33.4% alongside a net profit margin of 4.6% compared with 3.8% in the prior year. The company has seen revenue move from US$23.2b and EPS of US$0.013 in the FY 2023 trailing period to US$27.4b and EPS of roughly US$0.072 in the latest trailing 12 months. This sets the backdrop for investors to weigh earnings growth and margin expansion as the...
NYSE:LAW
NYSE:LAWSoftware

CS Disco Q4 Loss Of US$8.5 Million Tests Bullish Profitability Narratives

CS Disco (LAW) just closed out FY 2025 with Q4 revenue of US$41.2 million, a basic EPS loss of US$0.14, and a net income loss of US$8.5 million. On a trailing twelve month basis, revenue was US$156.8 million with a basic EPS loss of US$0.72 and a net income loss of US$44.4 million. The company’s quarterly revenue moved from US$36.3 million in Q3 2024 to US$41.2 million in Q4 2025, while basic EPS losses over that span ranged between US$0.42 and US$0.14 per quarter. For investors, the latest...
NYSE:FSS
NYSE:FSSMachinery

Federal Signal (FSS) Premium P/E Tests 10.9% Earnings Growth Narrative After FY 2025 Results

How Federal Signal’s FY 2025 Results Set the Tone for the Next Chapter Federal Signal (FSS) closed FY 2025 with fourth quarter revenue of US$597.1 million and basic EPS of US$1.00, alongside trailing twelve month revenue of about US$2.2 billion and EPS of US$4.06, giving investors a clear view of its recent earnings power. Over the past six reported quarters, the company has seen revenue move from US$472 million in Q4 2024 to US$597.1 million in Q4 2025. Quarterly EPS ranged from US$0.76 in...
NasdaqGS:ALLT
NasdaqGS:ALLTSoftware

Allot (NasdaqGS:ALLT) Profitable FY 2025 EPS Challenges Skeptical Narratives On Earnings Durability

Allot (NasdaqGS:ALLT) has wrapped up FY 2025 with Q4 revenue of US$28.4 million and basic EPS of US$0.06, alongside trailing twelve month revenue of US$102.0 million and EPS of US$0.08. Over the past few quarters, the company has reported revenue of US$24.9 million in Q4 2024, followed by US$23.2 million in Q3 2024, and then US$23.2 million, US$23.2 million, US$24.1 million, US$26.4 million and US$28.4 million across FY 2025. Over the same period, quarterly EPS moved from US$0.01 in Q4 2024...
NYSE:PARR
NYSE:PARROil and Gas

Par Pacific Holdings (PARR) EPS Rebound To US$1.58 Tests Sustainability Of Bullish Narratives

Par Pacific Holdings (PARR) closed out FY 2025 with Q4 revenue of US$1.8 billion and basic EPS of US$1.58 on net income of US$77.7 million. Over the past four quarters, the company has reported revenue between US$1.7 billion and US$2.0 billion per quarter. Basic EPS moved from a quarterly loss of US$0.57 in Q1 2025 to a high of US$5.29 in Q3 2025, then finished at US$1.58 in Q4. For investors, that combination of solid Q4 profit and shifting EPS through the year highlights the question of how...
NasdaqGS:SOLS
NasdaqGS:SOLSChemicals

Assessing Solstice Advanced Materials (SOLS) Valuation After Its Recent Share Price Momentum

Solstice Advanced Materials (SOLS) has caught investor attention after a strong share price move over the past month, prompting a closer look at how its current valuation lines up with its recent financial profile. See our latest analysis for Solstice Advanced Materials. The recent move has come on top of an already strong run, with a 30 day share price return of 29.9% and a 90 day share price return of 72.8%. This suggests momentum has been building rather than fading around the current...
NasdaqGS:BATR.K
NasdaqGS:BATR.KEntertainment

Atlanta Braves Holdings Q3 Profit Highlights Ongoing Gap With Trailing Losses And Premium Valuation

Atlanta Braves Holdings (BATRK) has just posted its FY 2025 third quarter numbers, with revenue of $311.5 million, basic EPS of $0.48 and net income of $30.0 million, giving investors a clear snapshot of how the season is flowing through to the bottom line. The company has seen quarterly revenue move from $282.9 million and EPS of $0.47 in Q2 FY 2024 to $290.7 million and $0.16 in Q3 FY 2024, then to $311.5 million and $0.48 in Q3 FY 2025. This sets up a narrative in which investors are...
NYSE:RVLV
NYSE:RVLVSpecialty Retail

Revolve Group (RVLV) Margins Hold At 5% Challenging Bearish Profitability Narratives

Revolve Group (RVLV) has just posted its FY 2025 numbers, with fourth quarter revenue of US$324.4 million and basic EPS of US$0.26 on net income of US$18.6 million, capping a year where trailing twelve month revenue reached US$1.23 billion and EPS came in at US$0.87. The company has seen revenue move from US$293.7 million and EPS of US$0.17 in Q4 2024 to US$324.4 million and EPS of US$0.26 in Q4 2025, while trailing twelve month EPS stepped up from US$0.70 to US$0.87. This sets the backdrop...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead’s Arcellx Deal And HIV Data Reframe Growth And Valuation Story

Gilead Sciences (NasdaqGS:GILD) has agreed to acquire Arcellx in a $7.8b deal, expanding its presence in cell therapies for blood cancers. The acquisition adds a near-approval CAR T cell therapy candidate to Gilead’s oncology portfolio. Separately, Gilead reported new Phase 3 data for an investigational once daily, single tablet HIV regimen, showing noninferior efficacy and high tolerability versus existing treatments. For investors watching Gilead Sciences at a share price of $147.12,...
NasdaqGS:TBLA
NasdaqGS:TBLAInteractive Media and Services

Taboola.com (TBLA) Profitability Turn In Q4 Reinforces Bullish Earnings Narrative

Taboola.com (TBLA) closed out FY 2025 with Q4 revenue of US$522.3 million and basic EPS of US$0.17, alongside Q4 2024 figures of US$491.0 million in revenue and basic EPS of US$0.10. Over the latest reported periods, revenue has moved from US$433.0 million in Q3 2024 to US$496.8 million in Q3 2025, while basic EPS shifted from a loss of US$0.02 to a profit of US$0.02. This highlights a story in which improving profitability and tighter margins are front and center for investors assessing this...
NYSE:FVR
NYSE:FVRRetail REITs

FrontView REIT (FVR) Q4 2025 FFO Stability Tests Long Term Growth Narratives

FrontView REIT (FVR) has just wrapped up FY 2025 with Q4 total revenue of US$16.5 million and basic EPS of a US$0.19 loss, capping a trailing twelve month stretch that totaled US$66.0 million in revenue and basic EPS of US$0.18. Over the last few reported quarters, revenue has moved from US$15.5 million in Q4 2024 to US$16.5 million in Q4 2025, while quarterly EPS has swung between earnings of US$0.19 and losses of around US$0.16 as margins absorbed a large one off loss of US$17.6 million...
NYSE:BKV
NYSE:BKVOil and Gas

BKV (BKV) Profitability Turnaround To US$173.1 Million Tests High 69x P E Narrative

BKV (BKV) closed out FY 2025 with Q4 revenue of US$330.1 million and basic EPS of US$0.76, while trailing twelve month EPS sat at US$2.00 on revenue of US$1.0 billion and net income of US$173.1 million. Over the past year, revenue has moved from US$615.1 million and a loss of US$2.00 per share on the trailing twelve month basis in Q4 2024 to US$1.0 billion and EPS of US$2.00. This frames a clear shift in reported profitability for the period. For investors, that combination of higher sales,...
NYSE:VLN
NYSE:VLNSemiconductor

Valens Semiconductor (VLN) Quarterly Loss Of US$7.3 Million Underscores Profitability Concerns

Valens Semiconductor FY 2025 Earnings Snapshot Valens Semiconductor (VLN) just posted third quarter FY 2025 revenue of US$17.3 million with a basic EPS loss of US$0.07, alongside trailing twelve month revenue of US$67.9 million and a TTM basic EPS loss of US$0.29. The company has seen quarterly revenue move from US$13.6 million in Q2 2024 to US$17.3 million in Q3 2025, while quarterly EPS losses have ranged between US$0.07 and US$0.10 over the same stretch. Investors are likely to focus on...
NYSE:DIN
NYSE:DINHospitality

Dine Brands Global (DIN) Margin Hit To 3.8% Reinforces Bearish Profitability Concerns

Dine Brands Global (DIN) has laid out its FY 2025 scorecard with Q3 revenue of US$216.2 million and basic EPS of US$0.48, alongside net income of US$7.0 million, setting the tone for how the full year is shaping up. The company has seen quarterly revenue move from US$204.8 million in Q4 2024 to US$214.8 million in Q1 2025, US$230.8 million in Q2 2025, then US$216.2 million in Q3 2025. Over the same period, EPS shifted from US$0.34 to US$0.53, US$0.89 and then US$0.48. With trailing net profit...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Recursion Pharmaceuticals Q3 Loss Deepens Narrative Of Heavy Spending Over Limited US$5.2m Revenue

Recursion Pharmaceuticals (RXRX) just posted another heavily loss making quarter, with Q3 FY 2025 revenue of US$5.2 million against a net loss of US$162.3 million and basic EPS of a US$0.36 loss. The company has seen quarterly revenue move between US$26.1 million in Q3 FY 2024 and US$4.5 million in Q4 FY 2024, while quarterly EPS has ranged from a US$0.34 loss to a US$0.53 loss over that period. This underscores a business that is still in investment mode rather than profit harvesting. For...
NasdaqGS:ACLS
NasdaqGS:ACLSSemiconductor

Axcelis’ Softer Q4 2025 Results and 2026 Outlook Might Change The Case For Investing In Axcelis Technologies (ACLS)

Axcelis Technologies reported past fourth-quarter 2025 revenue of US$238.33 million and net income of US$34.3 million, alongside full-year 2025 revenue of US$839.05 million and net income of US$120.24 million, and later issued first-quarter 2026 guidance for about US$195 million in revenue and GAAP diluted EPS of US$0.38. The combination of weaker year-on-year results and more cautious near-term guidance gives investors fresh information on how Axcelis is managing softer semiconductor...
NasdaqGS:STX
NasdaqGS:STXTech

A Look At Seagate Technology Holdings (STX) Valuation After US$600m Exchangeable Note Conversion And Recent Momentum

Seagate Technology Holdings (STX) is back in focus after completing US$600 million in exchangeable senior note conversions into cash and ordinary shares, a capital structure move that arrives alongside upbeat third party commentary on its recent operating performance. See our latest analysis for Seagate Technology Holdings. The recent US$600 million exchangeable note conversion comes against a backdrop of strong share price momentum, with a 30-day share price return of 17.74% and a 90-day...
NYSE:GMED
NYSE:GMEDMedical Equipment

Is It Too Late To Consider Globus Medical (GMED) After Recent Share Price Strength?

If you are wondering whether Globus Medical's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. The stock last closed at US$96.22, with returns of 6.7% over the past week, 3.5% over the past month, 10.2% year to date and 20.3% over the last year, plus 66.2% over three years and 56.4% over five years. Recent attention on Globus Medical has centered on its role in the healthcare sector and how investors are...
NYSE:BHE
NYSE:BHEElectronic

Benchmark Electronics (BHE) Is Up 5.3% After Pivot Toward Higher-Margin Engineering Programs And New Facility

Recently, Benchmark Electronics filed its 2025 Form 10-K outlining resilient operations, stronger sales in Aerospace, Defense, and Medical, a completed manufacturing shift to a new Guadalajara facility, and continued use of a US$700 million credit agreement to support debt reduction, buybacks, and dividends. The company is increasingly concentrating on complex, low-to-medium-volume manufacturing in regulated markets while tilting its mix toward higher-margin, engineering-heavy programs that...